Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy

Neurology

Volumn 75, Issue 21, 2010, Pages 1896-1903

  Dali, C ^a   Hanson, L G ^b,c   Barton, N W ^d   Fogh, J ^e   Nair, N ^d   Lund, A M ^a  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d SHIRE   (United States)

^e Zymenex AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; CREATININE; N ACETYLASPARTIC ACID;

ARTICLE; BRAIN LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; DEMYELINATION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; FUNCTIONAL STATUS; HEAD MOVEMENT; HUMAN; LIPOGENESIS; LYSOSOME STORAGE DISEASE; MALE; METABOLITE; METACHROMATIC LEUKODYSTROPHY; MOTOR PERFORMANCE; NERVOUS SYSTEM; NEUTRON ACTIVATION ANALYSIS; OLIGODENDROGLIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SUPINE POSITION; WHITE MATTER;

EID: 78649999667     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181feb217     Document Type: Article

References (40)

1. Gieselmann V. Metachromatic leukodystrophy: Genetics, pathogenesis and therapeutic options. Acta Paediatr Suppl 2008;97:15-21.
2. von Figura K, Steckel F, Hasilik A. Juvenile and adult metachromatic leukodystrophy: Partial restoration of arylsulfatase A (cerebroside sulfatase) activity by inhibitors of thiol proteinases. Proc Natl Acad Sci USA 1983;80:6066-6070.
3. Biffi A, Cesani M, Fumagalli F, et al. Metachromatic leukodystrophy: Mutation analysis provides further evidence of genotype-phenotype correlation. Clin Genet 2008;74: 349-357.
4. von Figura K, Gieselmann V, Jaeken J. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill; 2001:3695-3723.
5. Kolodny EH, Fluharty AL. Metachromatic leukodystrophy and multiple sulfatase deficiency: Sulfatide lipidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York: McGraw-Hill; 1995:2693-2739.
6. Schiffmann R, van der Knaap MS. Invited article: An MRIbased approach to the diagnosis of white matter disorders. Neurology 2009;72:750-759.
7. Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: A scoring method for brain MR observations. Am J Neuroradiol 1994;15:1761-1766.
8. Seeger U, Klose U, Mader I, Grodd W, Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn Reson Med 2003;49:19-28.
9. Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005;2: 197-214.
10. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 2007;81: 89-131.
11. De Stefano N, Filippi M, Miller D, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69:1942-1952.
12. Rosenbaum PL, Palisano RJ, Bartlett DJ, Galuppi BE, Russell DJ. Development of the Gross Motor Function Classification System for cerebral palsy. Dev Med Child Neurol 2008;50:249-253.
13. Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: Evidence of reliability and validity. Phys Ther 2000;80:873-885.
14. Tieman BL, Palisano RJ, Sutlive AC. Assessment of motor development and function in preschool children. Ment Retard Dev Disabil Res Rev 2005;11:189-196.
15. Klein-Tasman BP, Phillips KD, Lord C, Mervis CB, Gallo FJ. Overlap with the autism spectrum in young children with Williams syndrome. J Dev Behav Pediatr 2009;30: 289-299.
16. Akshoomoff N. Use of the Mullen Scales of Early Learning for the assessment of young children with autism spectrum disorders. Child Neuropsychol 2006;12:269-277.
17. Hanson LG, Schaumburg K, Paulson OB. Reconstruction strategy for echo planar spectroscopy and its application to partially undersampled imaging. Magn Reson Med 2000; 44:412-417.
18. Mathiesen HK, Jonsson A, Tscherning T, et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006;63:533-536.
19. Mathiesen HK, Tscherning T, Sorensen PS, et al. Multislice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. Magn Reson Med 2005;53:750-759.
20. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman and Hall; 1993.
21. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002; 51:51-58.
22. Horska A, Kaufmann WE, Brant LJ, Naidu S, Harris JC, Barker PB. In vivo quantitative proton MRSI study of brain development from childhood to adolescence. J Magn Reson Imaging 2002;15:137-143.
23. Pouwels PJ, Brockmann K, Kruse B, et al. Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatr Res 1999;46:474-485.
24. Inglese M, Rusinek H, George IC, Babb JS, Grossman RI, Gonen O. Global average gray and white matter N-acetylaspartate concentration in the human brain. Neuroimage 2008;41:270-276.
25. Liu HM. Ultrastructure of central nervous system lesions in metachromatic leukodystrophy with special reference to morphogenesis. J Neuropathol Exp Neurol 1968;27:624-644.
26. Gregoire A, Perier O, Dustin P Jr. Metachromatic leukodystrophy, an electron microscopic study. J Neuropathol Exp Neurol 1966;25:617-636.
27. Hanefeld FA, Brockmann K, Pouwels PJ, Wilken B, Frahm J, Dechent P. Quantitative proton MRS of Pelizaeus-Merzbacher disease: Evidence of dys- and hypomyelination. Neurology 2005;65:701-706.
28. Bonavita S, Schiffmann R, Moore DF, et al. Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations. Neurology 2001;56:785-788. (Pubitemid 32240103)
29. Brockmann K, Dechent P, Wilken B, Rusch O, Frahm J, Hanefeld F. Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease. Neurology 2003;60:819-825.
30. Van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white matter disorders: Quantitative MR imaging and spectroscopy. Radiology 2006;241:510-517.
31. Eichler FS, Itoh R, Barker PB, et al. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: Initial experience. Radiology 2002; 225:245-252.
32. Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569-573.
33. Ozturk A, Degaonkar M, Matson MA, Wells CT, Mahone EM, Horska A. Proton MR spectroscopy correlates of frontal lobe function in healthy children. Am J Neuroradiol 2009;30:1308-1314.
34. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215-226.
35. Grodd W, Krageloh-Mann I, Klose U, Sauter R. Metabolic and destructive brain disorders in children: Findings with localized proton MR spectroscopy. Radiology 1991; 181:173-181.
36. Garnett MR, Blamire AM, Rajagopalan B, Styles P, Cadoux- Hudson TA. Evidence for cellular damage in normalappearing white matter correlates with injury severity in patients following traumatic brain injury: A magnetic resonance spectroscopy study. Brain 2000;123:1403-1409.
37. Sevin C, Aubourg P, Cartier N. Enzyme, cell and genebased therapies for metachromatic leukodystrophy. J Inherit Metab Dis 2007;30:175-183.
38. Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006;116:3070-3082.
39. Matzner U, Herbst E, Hedayati KK, et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005;14:1139-1152.
40. Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004;1:189-195.